Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

NGM Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic, and ophthalmic diseases. NGM Biopharmaceuticals serves medical industry in the United States.
Website: ngmbio.com



Growth: Bad revenue growth rate -94.4%, there is slowdown compared to average historical growth rates -44.2%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -3 625.0%. Gross margin is high, +49.7%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of $0 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -7.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 156.5% higher than minimum and 68.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -178.1x by EV / Sales multiple

Key Financials (Download financials)

Ticker: NGM
Share price, USD:  (0.0%)1.54
year average price 1.5400  


year start price 1.5400 2025-02-14

max close price 1.5400 2025-02-14

min close price 1.5400 2025-02-14

current price 1.5400 2026-02-13
Common stocks: 79 950 000

Dividend Yield:  0.0%
EV / Sales: 16.0x
Margin (EBITDA LTM / Revenue): -3 625.0%
Fundamental value created in LTM:
Market Cap ($m): 123
Net Debt ($m): -59
EV (Enterprise Value): 64
Price to Book: 0.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-19GlobeNewsWire

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

2024-03-11Zacks Investment Research

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates

2024-03-07Zacks Investment Research

Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season

2023-11-02Zacks Investment Research

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates

2023-08-03Zacks Investment Research

NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates

2023-05-25GlobeNewsWire

NGM Bio to Participate in Upcoming Investor Conferences
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol NGM NGM NGM NGM NGM NGM NGM NGM NGM
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
filingDate 2024-03-11 2023-02-28 2022-03-01 2021-03-15 2020-03-17
acceptedDate 2024-03-11 16:15:03 2023-11-02 16:12:10 2023-08-03 16:11:38 2023-05-04 16:20:39 2023-02-28 16:20:02 2022-11-03 16:20:09 2022-03-01 16:25:17 2021-03-15 16:49:26 2020-03-17 16:33:23
fiscalYear 2023 2022 2021 2020 2019
period FY Q3 Q2 Q1 FY Q3 FY FY FY
revenue 4M 582 000 1M 2M 55M 8M 78M 87M 104M
costOfRevenue 2M 500 000 1M 0 6M 0 8M 164M 129M
grossProfit 2M 82 000 304 000 2M 49M 8M 70M -77M -26M
researchAndDevelopmentExpenses 112M 23M 32M 41M 181M 46M 162M 164M 129M
generalAndAdministrativeExpenses 38M 9M 10M 12M 41M 10M 37M 27M 24M
sellingAndMarketingExpenses -1M 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 37M 9M 10M 12M 41M 10M 37M 27M 24M
otherExpenses -234 000 -15 000 -134 000 -37 000 -132 000 0 -60 000 -593 000 -147 000
operatingExpenses 149M 32M 42M 52M 222M 56M 199M 191M 153M
costAndExpenses 151M 32M 42M 52M 222M 56M 199M 191M 153M
netInterestIncome 9M 0 420 000 2M 7M
interestIncome 9M 2M 2M 3M 4M 965 000 420 000 2M 7M
interestExpense 0 0 0 -3M 4M 965 000 0 0 0
depreciationAndAmortization 2M 535 000 559 000 609 000 4M 598 000 6M 7M 8M
ebitda -144M -30M -40M -50M -155M -48M -121M -104M -49M
ebit -147M -159M 0 0 0
nonOperatingIncomeExcludingInterest 0 -7M 0 0 0
operatingIncome -147M -31M -41M -50M -166M -48M -121M -104M -49M
totalOtherIncomeExpensesNet 4M 2M -134 000 3M 4M 1M 360 000 1M 7M
incomeBeforeTax -142M -29M -38M -48M -163M -47M -120M -102M -43M
incomeTaxExpense 0 0 -2M -3M -4M -1M -7M -8M -14M
netIncomeFromContinuingOperations -142M -159M -114M -94M -28M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncome -142M -29M -38M -45M -159M -46M -114M -94M -28M
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -142M -159M -114M -94M -28M
eps -1.73 -0.35 -0.46 -0.55 -1.99 -0.57 -1.48 -1.37 -0.57
epsDiluted -1.73 -1.99 -1.48 -1.37 -0.57
weightedAverageShsOut 82M 83M 82M 82M 80M 81M 77M 68M 50M
weightedAverageShsOutDil 82M 83M 82M 82M 80M 81M 77M 68M 50M
fillingDate 2023-11-02 2023-08-03 2023-05-04 2022-11-03
calendarYear 2023 2023 2023 2022
grossProfitRatio 0.141 0.214 1 1
ebitdaratio -52.399 -28.121 -22.338 -6.03
operatingIncomeRatio -53.318 -28.514 -22.338 -6.106
incomeBeforeTaxRatio -49.479 -26.888 -21.205 -5.974
netIncomeRatio -49.479 -26.888 -20.071 -5.842
epsdiluted -0.35 -0.46 -0.55 -0.57
link Link Link Link Link
finalLink Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol NGM NGM NGM NGM NGM NGM NGM NGM NGM
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
filingDate 2024-03-11 2023-02-28 2022-03-01 2021-03-15 2020-03-17
acceptedDate 2024-03-11 16:15:03 2023-11-02 16:12:10 2023-08-03 16:11:38 2023-05-04 16:20:39 2023-02-28 16:20:02 2022-11-03 16:20:09 2022-03-01 16:25:17 2021-03-15 16:49:26 2020-03-17 16:33:23
fiscalYear 2023 2022 2021 2020 2019
period FY Q3 Q2 Q1 FY Q3 FY FY FY
cashAndCashEquivalents 59M 51M 53M 68M 73M 101M 152M 147M 246M
shortTermInvestments 88M 115M 140M 163M 198M 199M 214M 148M 99M
cashAndShortTermInvestments 147M 166M 194M 231M 271M 300M 366M 295M 345M
netReceivables 58 000 0 736 000 1M 8M 4M 5M 6M 5M
accountsReceivables 0 0 0 0 0
otherReceivables 58 000 8M 5M 6M 5M
inventory 0 0 1M 1M 0 0 0 0 0
prepaids 0 0 0 0 0
otherCurrentAssets 9M 8M 9M 9M 10M 11M 8M 7M 6M
totalCurrentAssets 156M 177M 204M 243M 289M 316M 379M 308M 355M
propertyPlantEquipmentNet 7M 8M 9M 10M 11M 11M 14M 15M 19M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 2M 2M 2M 0 4M 0 1M 1M 2M
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 3M 5M 5M 7M 4M 9M 7M 5M 4M
totalNonCurrentAssets 12M 15M 16M 16M 19M 20M 23M 21M 25M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 169M 192M 221M 259M 307M 336M 402M 329M 380M
totalPayables 3M 8M 5M 10M 9M
accountPayables 3M 5M 6M 13M 8M 4M 5M 10M 9M
otherPayables 0 0 0 0 0
accruedExpenses 0 0 0 0 0
shortTermDebt 0 1M 3M 4M 5M 5M 5M 0 0
capitalLeaseObligationsCurrent 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 107 000 689 000 376 000 366 000 7M 18M 0 5M
otherCurrentLiabilities 17M 16M 19M 20M 34M 33M 33M 33M 26M
totalCurrentLiabilities 20M 22M 28M 38M 48M 49M 61M 43M 40M
longTermDebt 0 0 0 0 0 1M 5M 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 149 000 0 0 17M 0 -14M 0 6M 10M
totalNonCurrentLiabilities 149 000 0 0 17M 14M 1M 5M 6M 10M
otherLiabilities 0 0 0 -17M -14M 0 0 0 0
capitalLeaseObligations 0 0 3M 4M 0 7M 0 0 0
totalLiabilities 20M 22M 28M 38M 48M 50M 67M 49M 50M
treasuryStock 0 0 0 0 0
preferredStock 0 0 0 0 0 0 0 0 380M
commonStock 83 000 83 000 83 000 82 000 82 000 82 000 78 000 71 000 67 000
retainedEarnings -724M -696M -668M -629M -582M -545M -419M -299M -196M
additionalPaidInCapital 0 0 0 0 0
accumulatedOtherComprehensiveIncomeLoss 18 000 -78 000 -149 000 -97 000 -302 000 -915 000 -129 000 4000 25 000
otherTotalStockholdersEquity 873M 841M 755M 579M 146M
totalStockholdersEquity 149M 170M 192M 221M 260M 286M 336M 280M 331M
totalEquity 149M 170M 192M 221M 260M 286M 336M 280M 331M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 169M 192M 221M 259M 307M 336M 402M 329M 380M
totalInvestments 91M 115M 140M 163M 202M 199M 216M 150M 101M
totalDebt 0 1M 3M 4M 5M 7M 10M 0 0
netDebt -59M -50M -51M -63M -68M -95M -141M -147M -246M
fillingDate 2023-11-02 2023-08-03 2023-05-04 2022-11-03
calendarYear 2023 2023 2023 2022
othertotalStockholdersEquity 866M 860M 850M 832M
totalLiabilitiesAndStockholdersEquity 192M 221M 259M 336M
link Link Link Link Link
finalLink Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol NGM NGM NGM NGM NGM NGM NGM NGM NGM
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
filingDate 2024-03-11 2023-02-28 2022-03-01 2021-03-15 2020-03-17
acceptedDate 2024-03-11 16:15:03 2023-11-02 16:12:10 2023-08-03 16:11:38 2023-05-04 16:20:39 2023-02-28 16:20:02 2022-11-03 16:20:09 2022-03-01 16:25:17 2021-03-15 16:49:26 2020-03-17 16:33:23
fiscalYear 2023 2022 2021 2020 2019
period FY Q3 Q2 Q1 FY Q3 FY FY FY
netIncome -142M -29M -38M -48M -163M -47M -120M -102M -43M
depreciationAndAmortization 2M 535 000 559 000 609 000 4M 598 000 6M 7M 8M
deferredIncomeTax 5M -1M -2M 0 0 0 4M -128 000 -1M
stockBasedCompensation 29M 6M 7M 9M 32M 8M 26M 16M 13M
changeInWorkingCapital -18M -4M -9M -3M -21M 10M 4M -4M -18M
accountsReceivables 8M 736 000 521 000 0 -3M 0 -3M 5M -2M
inventory 0 -736 000 -521 000 0 3M 0 3M -5M 2M
accountsPayables -5M -931 000 -7M 5M 3M -3M -4M 910 000 4M
otherWorkingCapital -21M -4M -2M -8M -24M 13M 9M -5M -22M
otherNonCashItems -7M 554 000 1M -477 000 3M 660 000 7M 613 000 98 000
netCashProvidedByOperatingActivities -132M -27M -40M -42M -144M -28M -73M -83M -41M
investmentsInPropertyPlantAndEquipment -1M -290 000 -104 000 -670 000 -2M -310 000 -2M -2M -3M
acquisitionsNet 0 -27M -25M 0 -16M 0 70M 49M -52M
purchasesOfInvestments -105M -23M -35M -14M -273M -28M -293M -178M -134M
salesMaturitiesOfInvestments 221M 50M 59M 51M 289M 64M 224M 129M 187M
otherInvestingActivities 0 16M -70M -49M 52M
netCashProvidedByInvestingActivities 114M 14M -72M -51M 49M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 0 0 0 0
netCommonStockIssuance 0 0 0 0 0
commonStockIssuance 2M 3M 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 2M 54M 150M 36M 181M
netCashProvidedByFinancingActivities 2M 54M 150M 36M 181M
effectOfForexChangesOnCash 1M 0 0 0 0 0 0 0 0
netChangeInCash -15M -295 000 -14M -6M -76M 41M 5M -99M 188M
cashAtEndOfPeriod 59M 57M 57M 72M 77M 105M 153M 149M 247M
cashAtBeginningOfPeriod 73M 57M 72M 77M 153M 65M 149M 247M 59M
operatingCashFlow -132M -27M -40M -42M -144M -28M -73M -83M -41M
capitalExpenditure -1M -290 000 -104 000 -670 000 -2M -310 000 -2M -2M -3M
freeCashFlow -133M -27M -40M -42M -146M -28M -75M -85M -45M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0
fillingDate 2023-11-02 2023-08-03 2023-05-04 2022-11-03
calendarYear 2023 2023 2023 2022
otherInvestingActivites 27M 25M 0 0
netCashUsedForInvestingActivites 27M 25M 36M 35M
debtRepayment 0 0 0 0
commonStockIssued 0 1M 279 000 0
dividendsPaid 0 0 0 0
otherFinancingActivites 0 0 0 33M
netCashUsedProvidedByFinancingActivities 0 1M 279 000 33M
link Link Link Link Link
finalLink Link Link Link Link

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2024-03-11 16:15 ET
NGM Biopharmaceuticals published news for 2023 q4
SEC form 8
2024-03-11 16:13 ET
NGM Biopharmaceuticals reported for 2023 q4
SEC form 8
2024-03-11 16:13 ET
NGM Biopharmaceuticals published news for 2023 q4
SEC form 10
2024-03-11 00:00 ET
NGM Biopharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 16:12 ET
NGM Biopharmaceuticals reported for 2023 q3
SEC form 8
2023-11-02 00:00 ET
NGM Biopharmaceuticals reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
NGM Biopharmaceuticals reported for 2023 q3
SEC form 10
2023-08-03 16:11 ET
NGM Biopharmaceuticals reported for 2023 q2
SEC form 6
2023-08-03 16:07 ET
NGM Biopharmaceuticals reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
NGM Biopharmaceuticals reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
NGM Biopharmaceuticals reported for 2023 q2
SEC form 6
2023-06-08 06:06 ET
NGM Biopharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
NGM Biopharmaceuticals reported for 2023 q1
SEC form 10
2023-05-04 00:00 ET
NGM Biopharmaceuticals reported for 2023 q1
SEC form 6
2023-04-04 16:06 ET
NGM Biopharmaceuticals published news for 2023 q1
SEC form 6
2023-03-01 07:50 ET
NGM Biopharmaceuticals published news for 2022 q4
SEC form 10
2023-02-28 16:20 ET
NGM Biopharmaceuticals reported for 2022 q4
SEC form 6
2023-02-28 16:13 ET
NGM Biopharmaceuticals reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
NGM Biopharmaceuticals reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
NGM Biopharmaceuticals reported for 2022 q4
SEC form 6
2022-12-20 16:06 ET
NGM Biopharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 16:20 ET
NGM Biopharmaceuticals reported for 2022 q3
SEC form 6
2022-11-03 16:12 ET
NGM Biopharmaceuticals reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
NGM Biopharmaceuticals reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
NGM Biopharmaceuticals reported for 2022 q3
SEC form 6
2022-10-17 07:40 ET
NGM Biopharmaceuticals published news for 2022 q3
SEC form 8
2022-10-17 00:00 ET
NGM Biopharmaceuticals published news for 2022 q3
SEC form 10
2022-08-04 16:32 ET
NGM Biopharmaceuticals reported for 2022 q2
SEC form 6
2022-08-04 16:13 ET
NGM Biopharmaceuticals published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
NGM Biopharmaceuticals reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
NGM Biopharmaceuticals reported for 2022 q2
SEC form 6
2022-07-13 16:07 ET
NGM Biopharmaceuticals published news for 2022 q2
SEC form 6
2022-06-30 16:01 ET
NGM Biopharmaceuticals published news for 2022 q1
SEC form 6
2022-05-24 17:01 ET
NGM Biopharmaceuticals published news for 2022 q1
SEC form 6
2022-05-20 16:50 ET
NGM Biopharmaceuticals published news for 2022 q1
SEC form 10
2022-05-05 16:32 ET
NGM Biopharmaceuticals reported for 2022 q1
SEC form 6
2022-05-05 16:22 ET
NGM Biopharmaceuticals published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
NGM Biopharmaceuticals reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
NGM Biopharmaceuticals reported for 2022 q1
SEC form 6
2022-04-28 17:07 ET
NGM Biopharmaceuticals published news for 2022 q1
SEC form 6
2022-04-06 16:13 ET
NGM Biopharmaceuticals published news for 2022 q1
SEC form 6
2022-03-10 17:00 ET
NGM Biopharmaceuticals published news for 2021 q4
SEC form 10
2022-03-01 16:25 ET
NGM Biopharmaceuticals published news for 2021 q4
SEC form 6
2022-03-01 16:11 ET
NGM Biopharmaceuticals published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
NGM Biopharmaceuticals published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
NGM Biopharmaceuticals published news for 2021 q4
SEC form 6
2021-11-04 16:51 ET
NGM Biopharmaceuticals published news for 2021 q3
SEC form 6
2021-11-04 16:49 ET
NGM Biopharmaceuticals published news for 2021 q3
SEC form 6
2021-11-04 16:43 ET
NGM Biopharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 16:22 ET
NGM Biopharmaceuticals published news for 2021 q3
SEC form 6
2021-11-04 16:16 ET
NGM Biopharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
NGM Biopharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
NGM Biopharmaceuticals published news for 2021 q3
SEC form 10
2021-08-05 16:31 ET
NGM Biopharmaceuticals published news for 2021 q2
SEC form 6
2021-08-05 16:17 ET
NGM Biopharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
NGM Biopharmaceuticals published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
NGM Biopharmaceuticals published news for 2021 q2
SEC form 6
2021-07-01 07:26 ET
NGM Biopharmaceuticals published news for 2021 q2
SEC form 6
2021-06-10 17:27 ET
NGM Biopharmaceuticals published news for 2021 q1
SEC form 6
2021-05-24 07:09 ET
NGM Biopharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 16:27 ET
NGM Biopharmaceuticals published news for 2021 q1
SEC form 6
2021-05-06 16:16 ET
NGM Biopharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
NGM Biopharmaceuticals published news for 2021 q1
SEC form 6
2021-04-28 16:36 ET
NGM Biopharmaceuticals published news for 2021 q1
SEC form 6
2021-04-28 16:26 ET
NGM Biopharmaceuticals published news for 2021 q1
SEC form 6
2021-03-15 16:50 ET
NGM Biopharmaceuticals published news for 2020 q4
SEC form 10
2021-03-15 16:49 ET
NGM Biopharmaceuticals published news for 2020 q4
SEC form 6
2021-03-04 16:14 ET
NGM Biopharmaceuticals published news for 2020 q4
SEC form 6
2021-01-06 16:24 ET
NGM Biopharmaceuticals published news for 2020 q4
SEC form 10
2020-11-12 16:36 ET
NGM Biopharmaceuticals published news for 2020 q3
SEC form 6
2020-11-12 16:32 ET
NGM Biopharmaceuticals published news for 2020 q3